Eureka-AI is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Eureka AI

7431 results about "Toxin" patented technology

A toxin is a poisonous substance produced within living cells or organisms; synthetic toxicants created by artificial processes are thus excluded. The term was first used by organic chemist Ludwig Brieger (1849–1919), derived from the word toxic.

Application of lipid vehicles and use for drug delivery

InactiveUS7063860B2Reduce and prevent antibody-mediated resistanceIncrease stimulationBiocideAntipyreticAnticarcinogenCapsaicin
The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.

Assessing blood brain barrier dynamics or identifying or measuring selected substances or toxins in a subject by analyzing Raman spectrum signals of selected regions in the eye

InactiveUS6574501B2Reduced energy/density exposure ratingImproved margin of safetyRaman scatteringDiagnostic recording/measuringConjunctivaNon invasive
A non-invasive method for analyzing the blood-brain barrier includes obtaining a Raman spectrum of a selected portion of the eye and monitoring the Raman spectrum to ascertain a change to the dynamics of the blood brain barrier. Also, non-invasive methods for determining the brain or blood level of an analyte of interest, such as glucose, drugs, alcohol, poisons, and the like, comprises: generating an excitation laser beam (e.g., at a wavelength of 600 to 900 nanometers); focusing the excitation laser beam into the anterior chamber of an eye of the subject so that aqueous humor, vitreous humor, or one or more conjunctiva vessels in the eye is illuminated; detecting (preferably confocally detecting) a Raman spectrum from the illuminated portion of the eye; and then determining the blood level or brain level (intracranial or cerebral spinal fluid level) of an analyte of interest for the subject from the Raman spectrum. In certain embodiments, the detecting step may be followed by the step of subtracting a confounding fluorescence spectrum from the Raman spectrum to produce a difference spectrum; and determining the blood level and/or brain level of the analyte of interest for the subject from that difference spectrum, preferably using linear or nonlinear multivariate analysis such as partial least squares analysis. Apparatus for carrying out the foregoing methods are also disclosed.

Composite probiotics micro-ecological formulation and preparation method

The invention relates to a composite probiotic bacterium microecological preparation and a preparation method thereof. The preparation is prepared by mixing 1.0 to 20 percent of composite microbial bacterium powder, 5.0 to 50 percent of composite oligosaccharide, 30 to 80 percent of auxiliary protective carrier and 0.1 to 0.2 percent of edible essence. The composite probiotic bacterium microecological preparation is prepared from a beneficial microbial preparation and a microbial growth-promoting factor, namely the oligosaccharide, through special combination and technological recombination. The composite probiotic bacterium microecological preparation has the advantages that beneficial active bacteria and the oligosaccharide promote each other, so that the composite probiotic bacterium microecological preparation has the advantages of obviously improving the microecological environment of the whole intestine and contributing to the digestion, preventing and treating intestine diseases, treating diarrhea, chronic diarrhea, diarrhea which can not be cured by antibiotic, constipation, dyspepsia and abdominal distension which are caused by intestine dysbacteriosis, recovering the intestine flora balance, protecting the liver, reinforcing the functions of detoxication and toxin expulsion of the liver, reinforcing the disease prevention and resistance such as the resistance of human body, and the like.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products